Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Perspective Therapeutics (CATX) Shares Outstanding (Diluted Average) (2023 - 2025)

Perspective Therapeutics (CATX) has disclosed Shares Outstanding (Diluted Average) for 3 consecutive years, with $73.8 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 14.57% to $73.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $73.8 million through Dec 2025, up 14.57% year-over-year, with the annual reading at $73.8 million for FY2025, 14.57% up from the prior year.
  • Shares Outstanding (Diluted Average) hit $73.8 million in Q4 2025 for Perspective Therapeutics, roughly flat from $73.6 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $228.6 million in Q1 2023 to a low of $26.3 million in Q3 2023.
  • Historically, Shares Outstanding (Diluted Average) has averaged $71.2 million across 3 years, with a median of $68.6 million in 2024.
  • Biggest YoY gain for Shares Outstanding (Diluted Average) was 168.32% in 2024; the steepest drop was 78.34% in 2024.
  • Year by year, Shares Outstanding (Diluted Average) stood at $26.8 million in 2023, then soared by 140.72% to $64.4 million in 2024, then increased by 14.57% to $73.8 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for CATX at $73.8 million in Q4 2025, $73.6 million in Q3 2025, and $74.2 million in Q2 2025.